Page last updated: 2024-11-03

riluzole and Niemann-Pick Disease, Type C

riluzole has been researched along with Niemann-Pick Disease, Type C in 1 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Niemann-Pick Disease, Type C: An autosomal recessive lipid storage disorder that is characterized by accumulation of CHOLESTEROL and SPHINGOMYELINS in cells of the VISCERA and the CENTRAL NERVOUS SYSTEM. Type C (or C1) and type D are allelic disorders caused by mutation of the NPC1 gene, which encodes a protein that mediates intracellular cholesterol transport from LYSOSOMES. Clinical signs include hepatosplenomegaly and chronic neurological symptoms. Type D is a variant in people with a Nova Scotia ancestry.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cougnoux, A1
Yerger, JC1
Fellmeth, M1
Serra-Vinardell, J1
Navid, F1
Wassif, CA1
Cawley, NX1
Porter, FD1

Other Studies

1 other study available for riluzole and Niemann-Pick Disease, Type C

ArticleYear
Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
    Molecular genetics and metabolism, 2021, Volume: 134, Issue:4

    Topics: Animals; Astrocytes; Ceftriaxone; Cells, Cultured; Disease Models, Animal; Excitatory Amino Acid Tra

2021